AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as ...
OCALA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Paul Goepfert, MD, of the University of Alabama-Birmingham (“UAB”), has agreed to act as the Principal Investigator for …